Benazepril: Nursing Drug Guide, Angioedema & Hyperkalemia
ACE inhibition lowers blood pressure, but the bedside risks nurses must not miss are angioedema with airway threat, hyperkalemia and acute kidney injury—especially with NSAIDs, potassium supplements, or dehydration—and the boxed warning to stop benazepril as soon as pregnancy is detected.
The Lotensin boxed warning states that when pregnancy is detected, benazepril should be discontinued as soon as possible because drugs acting on the renin–angiotensin system can injure or cause death of the developing fetus. Separately, angioedema of the face, lips, tongue, glottis, or larynx—including fatal cases—has occurred with ACE inhibitors; discontinue immediately and escalate airway care when involvement threatens breathing. Serum potassium and renal function need periodic surveillance because RAS blockade predisposes to hyperkalemia and acute kidney injury, particularly with dehydration, NSAIDs, potassium supplements, potassium-sparing diuretics, or dual RAS inhibition.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Every benazepril administration should reconcile pregnancy possibility, airway symptoms after any swelling, and creatinine plus potassium trajectory when NSAIDs, aldosterone-antagonizing diuretics, or supplemental potassium are introduced—those layers cause the majority of preventable RAS-inhibitor harms nurses catch first.
Most common brand names
Benazepril is the generic name for this angiotensin-converting enzyme inhibitor. Common U.S. brand marketing uses Lotensin. Fixed-dose combinations with other antihypertensives exist in broader formularies; verify the precise product on each order because combination tablets may pair benazepril with agents such as a thiazide or a calcium channel blocker (for example combinations sometimes include amlodipine). Always trace both active ingredients through medication reconciliation rather than trusting look-alike bottle labels.
Why we give it — Indications
Lotensin prescribing information identifies its approved role as hypertension treatment to reduce blood pressure, which lowers the risk of fatal and nonfatal cardiovascular events—chiefly stroke and MI—in controlled hypertension trials aggregated across pharmacologic classes. Prescribing information states it may be used alone or combined with thiazide diuretics per clinician orders and guideline pathways followed by your service.
| Use | Detail |
|---|---|
| Blood pressure lowering | Lowering elevated blood pressure decreases cardiovascular risk trajectory; clinicians often layer multiple drug classes consistent with hypertension guidelines institutionalized locally. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Benazepril is absorbed and converted hepatically to benazeprilat, the primary ACE-blocking metabolite detailed in prescribing information. Inhibiting ACE reduces angiotensin II formation and lowers aldosterone-driven sodium retention—producing vasodilation plus modest potassium retention. ACE also degrades bradykinin; whether elevated bradykinin contributes both to blood pressure lowering and to ACE inhibitor cough is discussed in labeling. Bradykinin excess is clinically linked to nuisance dry cough and overlaps mechanistically with angioedema vigilance pathways.
Dosing overview
Doses below reflect the reviewed Lotensin label; titrate strictly to clinician orders and to blood pressure plus renal-electrolyte response. Estimated GFR informs starting dose selections described in prescribing information (eGFR trends support monitoring alongside serum creatinine).
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (blood pressure) | In single doses, hypertension reduction begins ≈ within 1 hour; trough values carry substantial carryover at 24 hours | Coach patients symptom expectations—dizziness orthostatically may appear earliest when volume depleted |
| Peak serum concentration | Benazepril peaks ≈ 0.5–1 h; active benazeprilat ≈ 1–2 h (delayed 2–4 h if taken with meals) | Timing relative to meals shifts bioavailability minimally but delays metabolite peaks—document patient pattern for consistent assessment windows |
| Half-life | Benazeprilat effective elimination half-life ≈10–11 h at steady-state (after 2–3 once-daily doses) | Missed doses: do not double; watch cumulative hypotension whenever diuretic doses change concurrently |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Identify pregnancy possibilities in patients of reproductive potential and verify aligned contraceptive or testing plans coordinated with prescribing teams
- Review baseline and recent renal function trajectory—especially when starting therapy, escalating dose, restarting after illness, or adding nephrotoxic or hyperkalemia-provoking drugs
- Screen for hypersensitivity histories to ACE inhibitors angioedema—even without prior ACE exposure per contraindications language
- Confirm whether interacting agents are present: NSAIDs, potassium supplements, potassium-sparing diuretics (for example concurrent spironolactone), dual RAS-blocking regimens (losartan or ARB combos), neprilysin inhibitors, lithium, immunosuppressant mTOR agents, oral hypoglycemic intensification predisposing hypoglycemia
Contraindications (FDA label summary)
- Hypersensitivity to benazepril or another ACE inhibitor
- History of angioedema including hereditary or idiopathic angioedema
- Combination with neprilysin inhibitor (example sacubitril)—do not start benazepril within 36 hours of switching from sacubitril/valsartan and vice versa
- Concurrent aliskiren with ACE inhibitors—including benazepril—in patients who have diabetes (label contraindication)
Important interactions
| Drug / scenario | Effect | Nursing action |
|---|---|---|
| Loop diuretics, thiazide diuretics | Excessive blood pressure drops—especially shortly after initiating diuretics or escalating ACE dose | Take orthostatic vitals closely first two weeks and after dose tweaks; escalate symptomatic hypotension or oliguria |
| Potassium-retaining therapies | Combined aldosterone suppression plus spironolactone-type agents or supplementation elevates hyperkalemia incidence | Ensure scheduled laboratory follow-up potassium review; withhold scheduled dose when clinically ordered for critical lab abnormalities pending prescriber contact |
| NSAID / COX-2 inhibitors | Reduced antihypertensive effect plus worsened renal impairment risk | Educate OTC avoidance without prescriber review; monitor creatinine and blood pressure pairing when unavoidable short courses emerge |
| Dual RAS inhibition | Higher renal dysfunction hypotension potassium disturbances | Scrutinize inpatient lists for simultaneous ACE ARB mineralocorticoid-direct renin blocker combinations violating policy; involve pharmacy early |
On a small screen, swipe or scroll sideways to see the full table.
Administration
- Lotensin is supplied exclusively as swallowed tablets labeled 10 mg, 20 mg, and 40 mg formulations
- Clinical pharmacokinetics allow administration with meals—food minimally changes overall exposure despite delaying benazeprilat peak times
- Alternative oral suspension compounding methodology exists exclusively for specialized pharmacy preparation per manufacturer instructions—not routine nursing mixing
Expected therapeutic response
- Blood pressures decline within two to four hours of individual doses achieving peak effects while sustaining twenty-four-hour control
- Combination with thiazide diuretics may blunt concurrent hypokalemia versus diuretics alone owing to tempered aldosterone signals
- Patients should articulate improved exercise tolerance contingent on cardiorespiratory comorbidity status once hypotension-mediated symptoms absent
Red flags — Stop and act
- Progressive airway-compromising lip swelling, tongue fullness, muffled speech, inspiratory difficulty—assume ACE inhibitor angioedema requiring immediate pathway activation
- Serum potassium climbing trend even before critical numeric threshold—coordinate repeat testing and cessation of potassium introductions
- New oliguria dizziness syncope collapsing perfusion pressures after initiating therapy or restarting post-acute illness referencing symptomatic orthostatic dizziness
- Creatinine elevations suggesting acute kidney injury attributable to RAS suppression volume depletion or renovascular physiology
- Life-threatening hypersensitivity manifestations consistent with dialysis membrane or venom-desensitization anaphylactoid reactions described in prescribing information—stop dialysis or procedure per protocol activate resuscitation resources
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Dizziness, headache, cough | Among most common (>5% placebo difference for headache dizziness in controlled summaries); cough leading discontinuations ≈0.5% | Teach positional caution; escalate persistent cough interfering safety or airway symptoms masquerading as benign cough |
| Anaphylactoid reactions dialysis membrane / desensitization context | Documented sentinel cases with ACE inhibitors undergoing specific high-flux dialysis or hymenoptera desensitization | Never minimize unusual intra-dialysis collapse—stop procedure treat supportively document medication class linkage |
| Severe cutaneous hepatic hematologic adverse events catalogued label | Stevens–Johnson erythema multiforme pancreatitis hemolytic anemia thrombocytopenia among postmarketing signal list | Immediately discontinue escalate laboratory evaluation when mucosal involvement bleeding infection stability compromise appear |
On a small screen, swipe or scroll sideways to see the full table.
Overdose management
Animal lethality thresholds described in prescribing information massively exceed therapeutic human doses; human overdose case series remain sparse labeling notes principal presentation likely manifests as hypotension.
Recommended supportive therapies (label)
- Intravenous saline infusion reversing intravascular depletion physiology
- Physiologic blood pressure augmentation using vasopressors—for example labeled catecholamine infusions—for refractory hypotension
- Gastric charcoal or gastrointestinal decontamination during narrow windows after ingestion
- Dialysis consideration because parent drug achieves only marginal dialytic clearance yet profoundly impaired kidneys may still need extracorporeal support during collapse physiology
Consult local poisoning or toxicology services per institutional policy when intentional overdose ingestion volume remains uncertain—even though labeling describes no reversal agent analogous to opioids or acetaminophen pathways.
Look-alike / sound-alike and error prevention
- Lotensin versus lisinopril / enalapril / quinapril: similar tablet coloring conventions across unrelated manufacturers—scanner verification mandatory
- Benazepril versus benztropine benzonatate benzocaine lexical families: avoid handwritten verbal-only orders ambiguous syllable counts
- Strength jumps: 10 mg, 20 mg, and 40 mg denominations cluster on automated dispensing carousel bins—tie-break using barcode witness policy
- Combination products: confirm whether order references benazepril monotherapy versus fixed combination containing second antihypertensive class inadvertently duplicated elsewhere
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Swallow intact | Standard Lotensin tablets are intended orally intact; compounded suspension exists only via pharmacy-specific preparation—not ad hoc crushed tablets unless pharmacy validates stability. |
| Meal pairing | Eating shifts benazeprilat peak latency without prohibiting coexistence consistent meals—steady daily pattern assists timing vitals trending. |
| Orthostatics | Volume-depleted hospitalized patients merit lying-standing blood pressure coupling during initial therapy weeks aligning warning language. |
| Airway adjunct readiness | Because angioedema may involve laryngeal structures rapidly, bedside teams benefit confirming emergency airway equipment availability zones when initiating new RAS inhibitor courses high-risk phenotype. |
| Pharmacy escalation triggers | Uncertainty about breastfeeding safety neprilysin transition windows lithium co-therapy dosing or suspension compounding should route through pharmacist corroboration before administration finishes. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pregnancy | Lotensin labeling links second- and third-trimester fetal injury to renin-angiotensin inhibition (renal hypoperfusion, oligohydramnios-associated complications, neonatal renal dysfunction). Nursing priority is cessation as soon as pregnancy is recognized or reliably suspected plus coordinated obstetric and prescribing follow-up. |
| Renovascular renal failure substrate | People whose renal blood flow relies on intact angiotensin II vasoconstriction (for example clinically suspected renovascular hypertension, clinically significant heart failure exacerbations, peri-infarction states, or clinically relevant volume contraction) risk precipitous creatinine elevations or oliguria once ACE inhibition starts—coordinate withholding rules per prescriber when labs or urine output worsen. |
| Pediatrics | Lotensin is not recommended in children younger than 6 years or when pediatric GFR is below 30 mL/min/1.73 m²; weight-based dosing applies only once both age and renal thresholds from labeling are met alongside specialist oversight. |
| Black ancestry monotherapy caveat | Randomized summaries referenced in prescribing information demonstrate smaller blood pressure reductions with ACE monotherapy alone in Black patients compared with non-Black cohorts—a factor prescribers use when tailoring combination strategies; nurses reinforce adherence and monitoring whenever regimens evolve. |
| Lactation | LactMed cites low breastmilk concentrations with modeled infant ingestion under 0.14% maternal weight-adjusted doses predominantly benazeprilat whose oral bioavailability clinically trivial—overall infant risk expectation low individualized discussion remains standard. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure, heart rate, and hydration status after initiation, dose increases, and restarts following intercurrent illness—labeling warns about symptomatic hypotension with volume depletion
- Serum creatinine and eGFR trends with electrolytes on the basic metabolic panel, including potassium
- Distinguish nuisance dry cough from progressive inspiratory distress, voice change, or swelling that may signal airway angioedema
- Blood glucose when antidiabetic therapy runs concurrently—labeling notes increased hypoglycemia risk, especially during the first month of combined use
Document
- Dose, route, time, indication, blood pressure, orthostatic symptoms, OTC NSAID use, and potassium supplements or salt substitutes
- Patient education on pregnancy avoidance, angioedema warning signs, dehydration risk, and hypoglycemia vigilance when diabetes medicines overlap
- Prescriber/pharmacist notifications, hold decisions, rapid response or airway interventions, and repeat lab trends
Patient teaching
- Discuss pregnancy planning—stop benazepril as soon as pregnancy is suspected or confirmed per the boxed warning
- Teach that facial, lip, or tongue swelling, noisy breathing, or swallowing difficulty means stop the drug and seek emergency care immediately—do not take another dose
- Do not start potassium supplements or potassium-containing salt substitutes without prescriber approval
- Report light-headedness, especially when standing; vomiting, diarrhea, heat exposure, and dehydration increase hypotension risk during early therapy
- Diabetic patients should monitor glucose more closely when ACE inhibitors are added—labeling warns of increased hypoglycemia risk with antidiabetic medicines
- Check with the care team before starting OTC NSAIDs such as ibuprofen—combined use can worsen renal function and blunt blood pressure control
The Hold Rule
Hold (clinician-aligned) dosing and escalate when:
- Pregnancy confirmed or suspected—discontinue immediately and notify the prescriber for obstetric follow-up
- Angioedema or any airway-threatening swelling of the face, lips, tongue, or throat—hold and escalate per emergency protocol
- Hyperkalemia, oliguria, or rising creatinine after dehydration, NSAID use, or dual RAS-blocking therapy—hold and clarify with prescriber/pharmacist
- Symptomatic hypotension, syncope, or shock until volume status and orders are reviewed
- Prohibited combinations on the MAR (dual RAS blockade, aliskiren with ACE inhibitor in diabetes, neprilysin inhibitor within 36-hour switch window, or suspected lithium toxicity)
Clinical practice integration and workflow
1. Stewardship checkpoints
- Barcode verify Lotensin strength before every administration pass
- Pair blood pressure captures with electrolyte renal panels after therapy starts or adjunct drugs change
- Screen admission medication lists for OTC renal stressors undocumented preadmission NSAID aspirin stacks
2. High-alert designation
Not universally classified institutional high-alertTreat benazepril with proportional vigilance analogous high-stakes cardiometabolic meds because fetal catastrophe airway angioedema and renal failure potentials exceed ordinary oral antihypertensive error tolerance.
3. Hold and question cues
- New tongue thickness lip asymmetry vocal changes—assume ACE inhibitor airway emergency until clarified
- Creatinine jump ≥30% clinician-defined institution thresholds after RAS initiation mandates hold clarification per policy
- Patient purchased OTC anti-inflammatory pills without informing team—coordinate pause teaching prescriber review
Teach-back prompts
- “Which swelling symptoms mean you skip further doses tonight?” (Patient should articulate face lip tongue airway difficulty emergency activation.)
- “Why should potassium salt substitutes worry your heart team?” (Patient references hyperkalemia coupling ACE inhibition.)
Pharmacist collaboration: Neprilysin sacubitril/valsartan transition windows NSAID unavoidable courses lithium dosing potassium binder coordination breastmilk counselling.
Prescriber / specialist: Resistant hypertension dialysis membrane planning angioedema recurrence pregnancy confirmation hyperkalemia refractory escalating renal insults unexplained hepatic enzyme cholestasis alerts.
🧠 Quick mental checklist
- Airway—is there progressing lip tongue voice change after today’s doses?
- Renal trajectory—Scr potassium sodium pairing volume status fair?
- Pregnancy possibility documentation contraception counseling complete?
- New NSAID potassium supplementation salt substitutes reviewed?
- If hypotensive after suspected overdose—is volume resuscitation pathway prepared though no antidote?
Benazepril NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for benazepril: open the inpatient case tabs (MAR, Labs, Vitals, Nursing notes), prioritize airway and renal-electrolyte decisions, practise cue recognition SATA, trending potassium and creatinine SATA, escalation matrix classification, stewardship MCQ reasoning, plus overdose cloze selection emphasising saline and vasopressor support—not a mythical antidote.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Lotensin (benazepril) 20 mg PO daily at bedtime—due tonight 2100
- Ibuprofen 400 mg PO three times daily (patient-supplied OTC) started yesterday for dental pain—documented MAR hold flag pending clinician review tomorrow
- Dihydropyridine calcium-channel blocker continuation each morning per prior chart reconciliation
- This morning BMP: serum creatinine 2.05 mg/dL (prior admission baseline 1.40 two days earlier)
- Potassium 4.6 mEq/L this morning versus 4.4 yesterday
- Historical eGFR near low-normal before admission (chart note)
- BP sitting 146/82 mm Hg, HR 74, RR 17, Temp 37.1 °C, SpO₂ 96% RA
- Dizziness reported transitioning supine-standing without syncope BP standing order pending day shift
- Patient worried about swelling after neighbor’s cousin “had swollen lips on Lisinopril”—denies swelling currently
- States continued ibuprofen use because pharmacy closed weekend
- 2100 meds arriving—student nurse asks whether benazepril should proceed before attending reviews creatinine uptrend
Answer key & rationale
Frequently asked questions
What is the most urgent ACE inhibitor complication nurses must not miss?
Angioedema involving the lips, tongue, glottis, or larynx can obstruct the airway—Lotensin labeling reports fatal reactions in some patients. Nurses should withhold further doses immediately on suspicion and coordinate airway-capable escalation per protocol until symptoms fully resolve.
Why does benazepril increase hyperkalemia risk?
Inhibiting the renin–angiotensin–aldosterone axis reduces aldosterone-mediated potassium elimination. Prescribing information recommends periodically monitoring potassium especially with renal impairment, diabetes mellitus, potassium-sparing drugs, supplemental potassium or potassium-containing salt substitutes, and overlapping RAS-blocking therapy.
What happens if pregnancy is detected?
Discontinue benazepril as soon as possible—the boxed warning states RAS-active drugs administered during pregnancy can injure or kill the fetus through oligohydramnios-related complications, neonatal renal failure, and related morbidity.
Is there an antidote for benazepril overdose?
No reversal agent appears in prescribing information—the expected principal human manifestation is hypotension treated with saline infusion vasopressor catecholamines when warranted plus supportive monitoring; activated charcoal gastric decontamination may be considered shortly after ingestion; dialysis limited but may support severely impaired kidneys.
What does LactMed say about breastfeeding?
LactMed reports low milk concentrations with modeled infant ingestion under roughly 0.14% maternal weight-adjusted dose largely as orally poorly absorbed benazeprilat; adverse infant effects would not ordinarily be expected though individualized clinician guidance persists.
Why should NSAIDs worry nurses administering benazepril?
Lotensin interactions warn NSAIDs including COX-2 selective agents may worsen renal function and blunt antihypertensive benefits—coordinate prescriber review when OTC anti-inflammatory exposures appear on medication histories.
References
-
U.S. National Library of Medicine. Lotensin (benazepril hydrochloride) tablet — prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e
-
Drugs and Lactation Database (LactMed). Benazepril. Bethesda (MD): National Institute of Child Health and Human Development; updated 2024.https://www.ncbi.nlm.nih.gov/books/NBK501116/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and pharmacist review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.